Using 68Ga-NY104 PET/CT to guide radiation therapy for advanced kidney cancer
Official title: Effect of 68Ga-NY104 and 18F-FDG PET/CT Guided Radiation Therapy Combined with Systemic Treatment in Patients with Clear Cell Renal Cell Carcinoma.
Run by Peking Union Medical College Hospital · NCT06613269 · Data updated 2026-11-12
This study is testing if a special imaging technique can help doctors better plan radiation therapy for people with advanced kidney cancer to improve their treatment outcomes.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | March 27, 2024 |
| Main results expected | September 2026 |
| Study ends | September 2028 |
| Registry record updated | September 27, 2024 |
| Trial ID | NCT06613269 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with histologically confirmed clear cell renal cell carcinoma who are eligible for radiation therapy.
✕Probably not a fit
Patients with brain metastasis, other uncontrolled malignancies, or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of using 68Ga-NY104 PET/CT imaging to guide radiation therapy in patients with advanced clear cell renal cell carcinoma (ccRCC). The approach combines targeted imaging with radiation treatment and standard systemic therapy to improve outcomes for patients with metastatic or recurrent ccRCC. The study aims to evaluate the diagnostic efficacy of the CAIX-targeted PET tracer and its impact on treatment response. Participants will undergo imaging and receive radiation therapy based on the results, with the goal of enhancing therapeutic effectiveness.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes for patients with advanced clear cell renal cell carcinoma.
How similar studies have gone: Previous studies have shown promising outcomes with similar approaches combining radiation therapy and systemic therapy in metastatic ccRCC.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * Histologically or cytologically confirmed clear cell renal cell carcinoma * Eligible for radiation therapy: no more than 10 lesions in total * Expected survival: over 3 months * ECOG: 0 or 1 * Sufficient organ function * Written informed consent Exclusion Criteria: * Brain metastasis/carcinomatous meningitis * Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer. * Pregnant or breastfeeding. * Active infection.
Where it's running
-
Peking University First Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Xianshu Gao, MD
- Email: gao7777@139.com
- Phone: +86 01083575641
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
Immune cell therapy for advanced clear cell kidney cancer
This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.
-
Theranostic pair labeled PD-32766D/T in CA9-positive clear cell kidney cancer
This study tests a matching diagnostic agent PD-32766D and a therapeutic agent PD-32766T in adults with CA9-expressing clear cell renal cell carcinoma to see if the treatment is safe and shows signs of effect.
-
LNK001 CAR T therapy in advanced clear cell kidney cancer
This study tests a CAR T-cell therapy called LNK001 to see if it can help people with advanced clear cell renal cell carcinoma after other treatments.
-
Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC
This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.